Table 1 Patient disposition
n (%) | Everolimus FAS (N = 120) | Everolimus pediatric subpopulation (N = 90) |
|---|---|---|
Patients | ||
 Completed study | 100 (83.3) | 79 (87.8) |
 Discontinued | 20 (16.7) | 11 (12.2) |
Primary reason for premature discontinuation | ||
 Adverse event(s) | 8 (6.7) a | 4 (4.4) |
 Otherb | 5 (4.2) | 3 (3.3) |
 Subject withdrew consent | 5 (4.2) | 2 (2.2) |
 Administrative problems | 1 (0.8) | 1 (1.1) |
 SEGA progression | 1 (0.8) | 1 (1.1) |